title: Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
authors.affiliation: Center of Internal Medicine, Goethe University, Frankfurt, Germany.
authors.forename: Nicola
authors.initials: N
authors.lastname: Gökbuget
authors.affiliation: Amgen Research (Munich) GmbH, Germany gerhardz@amgen.com.
authors.forename: Gerhard
authors.initials: G
authors.lastname: Zugmaier
authors.affiliation: Amgen Research (Munich) GmbH, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Klinger
authors.affiliation: Amgen Research (Munich) GmbH, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Kufer
authors.affiliation: Medical Department A, University of Münster, Germany.
authors.forename: Matthias
authors.initials: M
authors.lastname: Stelljes
authors.affiliation: Department for Internal Medicine III, University Ulm, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Viardot
authors.affiliation: Medical Department II, Christian-Albrechts University, Kiel, Germany.
authors.forename: Heinz A
authors.initials: HA
authors.lastname: Horst
authors.affiliation: Medical Department II, Christian-Albrechts University, Kiel, Germany.
authors.forename: Svenja
authors.initials: S
authors.lastname: Neumann
authors.affiliation: Medical Department II, Christian-Albrechts University, Kiel, Germany.
authors.forename: Monika
authors.initials: M
authors.lastname: Brüggemann
authors.affiliation: Department of Haematology, Cardiff University, Cardiff, UK.
authors.forename: Oliver G
authors.initials: OG
authors.lastname: Ottmann
authors.affiliation: Department for Hematology and Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Burmeister
authors.affiliation: Metronomia Clinical Research GmbH, München, Germany.
authors.forename: Dorothea
authors.initials: D
authors.lastname: Wessiepe
authors.affiliation: Department of Internal Medicine II, Universitätsklinikum, Würzburg, Germany.
authors.forename: Max S
authors.initials: MS
authors.lastname: Topp
authors.affiliation: Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Germany.
authors.forename: Ralf
authors.initials: R
authors.lastname: Bargou
mesh_terms: D000328:Adult; D000368:Aged; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000378:metabolism; D015870:Gene Expression; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics / Q000378:metabolism; D018365:Neoplasm, Residual; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012008:Recurrence; D016019:Survival Analysis; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; C113855:MLL-AF4 fusion protein, human; D015514:Oncogene Proteins, Fusion; D051788:Myeloid-Lymphoid Leukemia Protein; C510808:blinatumomab; D016044:Fusion Proteins, bcr-abl